Entering text into the input field will update the search result below

AVEO Oncology's tivozanib shows positive effect in early-stage liver cancer study; shares ahead 5%

Jan. 19, 2018 3:23 PM ETAVEO Pharmaceuticals, Inc. (AVEO) StockBy: Douglas W. House, SA News Editor9 Comments
  • AVEO Oncology (NASDAQ:AVEO +5.4%) is up on 30% higher volume in response to positive results from the Phase 1b portion of a Phase 1b/2 clinical trial assessing lead drug FOTIVDA (tivozanib) in patients with advanced unresectable hepatocellular carcinoma (HCC). The data were presented at the ASCO-GI Symposium in San Francisco.
  • Median progression-free survival (PFS) in 19 evaluable patients at week 24 was 5.5 months and 47% (n=9/19) had stable disease. The disease control rate (responders + those with stable cancer) was 63% (n=12/19), including four partial responders and eight with stable disease. Four subjects remained progression-free for over two years. Overall survival (OS) at month 6 and month 12 was 58% and 25%, respectively.
  • On the safety front, two patients experienced dose-limiting toxicities (Grade 3 mucositis and hypertension) upon receiving the 1.5 mg dose (highest) and withdrew from the study.
  • The 1.0 mg dose will be evaluated in the Phase 2 portion.
  • Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is designed to optimize VEGF blockade while minimizing toxic side effects.

Recommended For You

Related Stocks

SymbolLast Price% Chg
AVEO--
AVEO Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.